Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Current Assets (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Current Assets for 16 consecutive years, with $288.4 million as the latest value for Q1 2026.

  • Quarterly Current Assets rose 3.3% to $288.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $288.4 million through Jan 2026, up 3.3% year-over-year, with the annual reading at $288.4 million for FY2026, 3.3% up from the prior year.
  • Current Assets for Q1 2026 was $288.4 million at Usana Health Sciences, up from $264.1 million in the prior quarter.
  • The five-year high for Current Assets was $451.2 million in Q3 2024, with the low at $261.9 million in Q2 2025.
  • Average Current Assets over 5 years is $356.1 million, with a median of $365.1 million recorded in 2022.
  • The sharpest move saw Current Assets rose 15.55% in 2024, then tumbled 41.47% in 2025.
  • Over 5 years, Current Assets stood at $384.4 million in 2022, then rose by 8.68% to $417.7 million in 2023, then plummeted by 33.17% to $279.2 million in 2024, then decreased by 5.42% to $264.1 million in 2025, then rose by 9.22% to $288.4 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $288.4 million, $264.1 million, and $261.9 million for Q1 2026, Q3 2025, and Q2 2025 respectively.